Literature DB >> 34907908

HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia/lymphoma.

Benjy Jy Tan1,2,3, Kenji Sugata1, Omnia Reda1,2,3,4, Misaki Matsuo1,2, Kyosuke Uchiyama5, Paola Miyazato2, Vincent Hahaut6,7, Makoto Yamagishi8, Kaoru Uchimaru8, Yutaka Suzuki9, Takamasa Ueno10, Hitoshi Suzushima11, Hiroo Katsuya2,12, Masahito Tokunaga13, Yoshikazu Uchiyama14, Hideaki Nakamura15, Eisaburo Sueoka16, Atae Utsunomiya13,17, Masahiro Ono2,18, Yorifumi Satou1,2.   

Abstract

Human T cell leukemia virus type 1 (HTLV-1) mainly infects CD4+ T cells and induces chronic, persistent infection in infected individuals, with some developing adult T cell leukemia/lymphoma (ATL). HTLV-1 alters cellular differentiation, activation, and survival; however, it is unknown whether and how these changes contribute to the malignant transformation of infected cells. In this study, we used single-cell RNA-sequencing and T cell receptor-sequencing to investigate the differentiation and HTLV-1-mediated transformation of T cells. We analyzed 87,742 PBMCs from 12 infected and 3 uninfected individuals. Using multiple independent bioinformatics methods, we demonstrated the seamless transition of naive T cells into activated T cells, whereby HTLV-1-infected cells in an activated state further transformed into ATL cells, which are characterized as clonally expanded, highly activated T cells. Notably, the greater the activation state of ATL cells, the more they acquire Treg signatures. Intriguingly, the expression of HLA class II genes in HTLV-1-infected cells was uniquely induced by the viral protein Tax and further upregulated in ATL cells. Functional assays revealed that HTLV-1-infected cells upregulated HLA class II molecules and acted as tolerogenic antigen-presenting cells to induce anergy of antigen-specific T cells. In conclusion, our study revealed the in vivo mechanisms of HTLV-1-mediated transformation and immune escape at the single-cell level.

Entities:  

Keywords:  Infectious disease; Leukemias; MHC class 2; T cells; Virology

Mesh:

Substances:

Year:  2021        PMID: 34907908      PMCID: PMC8670839          DOI: 10.1172/JCI150472

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   19.456


  54 in total

1.  Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes.

Authors:  E Hanon; S Hall; G P Taylor; M Saito; R Davis; Y Tanaka; K Usuku; M Osame; J N Weber; C R Bangham
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

2.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Activated rat T cells synthesize and express functional major histocompatibility class II antigens.

Authors:  C P Broeren; M H Wauben; M A Lucassen; M Van Meurs; P J Van Kooten; C J Boog; E Claassen; W Van Eden
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

4.  Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state.

Authors:  T Sakai; K Nosaka; S Tamiya; S Koga; S Mita; M Uchino; H Mitsuya; M Matsuoka
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

5.  Reconstitution of anti-HIV effector functions of primary human CD8 T lymphocytes by transfer of HIV-specific alphabeta TCR genes.

Authors:  Takamasa Ueno; Mamoru Fujiwara; Hiroko Tomiyama; Masafumi Onodera; Masafumi Takiguchi
Journal:  Eur J Immunol       Date:  2004-12       Impact factor: 5.532

6.  Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).

Authors:  M Shimoyama
Journal:  Br J Haematol       Date:  1991-11       Impact factor: 6.998

7.  CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma.

Authors:  Seiichiro Kobayashi; Kazumi Nakano; Eri Watanabe; Tomohiro Ishigaki; Nobuhiro Ohno; Koichiro Yuji; Naoki Oyaizu; Satomi Asanuma; Makoto Yamagishi; Tadanori Yamochi; Nobukazu Watanabe; Arinobu Tojo; Toshiki Watanabe; Kaoru Uchimaru
Journal:  Clin Cancer Res       Date:  2014-04-11       Impact factor: 12.531

8.  HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+ T cells in virus-infected individuals.

Authors:  Yorifumi Satou; Atae Utsunomiya; Junko Tanabe; Masanori Nakagawa; Kisato Nosaka; Masao Matsuoka
Journal:  Retrovirology       Date:  2012-05-30       Impact factor: 4.602

9.  Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics.

Authors:  Kelly Street; Davide Risso; Russell B Fletcher; Diya Das; John Ngai; Nir Yosef; Elizabeth Purdom; Sandrine Dudoit
Journal:  BMC Genomics       Date:  2018-06-19       Impact factor: 3.969

10.  Trajectory-based differential expression analysis for single-cell sequencing data.

Authors:  Sandrine Dudoit; Lieven Clement; Koen Van den Berge; Hector Roux de Bézieux; Kelly Street; Wouter Saelens; Robrecht Cannoodt; Yvan Saeys
Journal:  Nat Commun       Date:  2020-03-05       Impact factor: 14.919

View more
  4 in total

1.  Identification and characterization of a novel enhancer in the HTLV-1 proviral genome.

Authors:  Takaharu Ueno; Kazuaki Monde; Kenji Sugata; Misaki Matsuo; Benjy Jek Yang Tan; Akhinur Rahman; Paola Miyazato; Kyosuke Uchiyama; Saiful Islam; Hiroo Katsuya; Shinsuke Nakajima; Masahito Tokunaga; Kisato Nosaka; Hiroyuki Hata; Atae Utsunomiya; Jun-Ichi Fujisawa; Yorifumi Satou
Journal:  Nat Commun       Date:  2022-05-03       Impact factor: 17.694

2.  The endogenous HBZ interactome in ATL leukemic cells reveals an unprecedented complexity of host interacting partners involved in RNA splicing.

Authors:  Mariam Shallak; Tiziana Alberio; Mauro Fasano; Maria Monti; Ilaria Iacobucci; Julien Ladet; Franck Mortreux; Roberto S Accolla; Greta Forlani
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

3.  TRAF3IP3 promotes glioma progression through the ERK signaling pathway.

Authors:  Qi Lin; Zhen Chen; Zhao-Li Shen; Fei Xue; Jia-Jun Qin; Xi-Peng Kang; Zhong-Rong Chen; Zhong-Yuan Xia; Liang Gao; Xian-Zhen Chen
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

Review 4.  T cell receptor repertoire analysis in HTLV-1-associated diseases.

Authors:  Annaliese Clauze; Yoshimi Enose-Akahata; Steven Jacobson
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.